2. P E T in URO-ONCOLOGY
Dr.V.SIVASUBRAMANIYAN
Dept. of Nuclear Medicine
SSSIHMS,PSN

30. URO-ONCOLOGY
 Ca. Prostate
 Ca. Bladder
 Ca.Testis
 Carcinoma Kidney

31. Ca Prostate
 PRIMARY
 FDG PET x C-11 Acetate PET
 METASTATIC
 FDG PET Vs C-11 Acetate PET
 RECURRENCE
 FDG PET = C-11 Acetate PET
 RESPONSE
 FDG

32. Ca Bladder
 PRIMARY
 No Role
 METASTATIC
 FDG PET Vs C-11 Acetate PET
 RECURRENCE
 FDG PET = C-11 Acetate PET
 RESPONSE
 FDG

37. MOLECULAR
IMAGING
WHAT?
WHY?
HOW?
WHEN?

38. WHAT I S .. D E F I N I T I
ON
 Molecular Imaging defined as IN-VIVO
characterisation and imaging of
 BIOLOGICAL PROCESSES at the
Cellular and Molecular
 with TARGETTED IMAING
TECHNIQUES.

39. HOW IS IT DIFFERE
NT
 CONVENTIONAL IMAGING-
EFFECT OF A PATHOLOGICAL
PROCESS IS DEPICTED
 MOLECULAR IMAGING – DEPICTS OR
DELINEATE S THE PATHOLOICAL
PROCESS CAUSING THE DISEASE

40. B A S I C T O O L ..
M OLECULAR PROBES
H IGH AFFINITY–2TYPES
 L.M.W– RECEPTOR LIGANDS
 ENZYME SUBSTRATES
 H.M.W- MONOCLONAL Ab
 RECOMBINENT PROTEINS

43. CRITICAL ISSUES
 CELL INTERNALISATION
A DE Q U A T E C O N C E N T R A T I O
N
R ETENTION FOR LONGER

44. METHODS OFIMAGI
NG
 NUCLEAR IMAGING
 MAGNETIC RESONANCE
 OPTICAL IMAGING

45. NUCLEAR STUDIES
 Na I SYMPORTER TRAPPING – I 131
 THYROID / LACTATING BREAST/
GASTRIC MUCOSA
 FDG PET
 HSV1- THYMIDINE KINASE

46. M. R . I
 MONOCRYSTALLINE IRON OXIDE
NANO-PARTICLES
 SECOND REPORTER SYSTEM
 ENZYMATIC HYDROLYSIS

48. OPTICAL IMAGING
 NEARINFRA RED FLUROSCENCE
IMAGING
 BIO-LUMINESCENT PROTEINS

55. SAISAHAVEERYAM
•N.M
Clinics N.P
•Bio-Tech
Comput.
Histopath •Bio-chem